Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences is poised for success with its innovative ABC platform and investigational medicines; including tarcocimab, the reformulated Zenkuda (tarcocimab tedromer) and KSI-501 (anti-VEGF, anti-IL-6), and KSI-101 (anti-VEGF/anti-IL-6 without biopolymer conjugate), all expected to have significant positive impact on the retinal therapeutics pipeline following the results of the Phase 3 DAYBREAK trial and future Phase 3 PEAK and PINNACLE trials for extended efficacy and durability beyond current standard treatments. Additionally, the company's financials and portfolio diversification, along with the potential for rapid adoption as a second-line or, in some cases, first-line treatment for different indications, make it an attractive investment with a Buy rating and target price of $58 per share based on a 25x multiple of taxed and diluted 2036 EPS of $8.93 discounted back to December 2026 at 13%, and an NPV discounted cash flow between 2026-2036 of $50.50 per share, with a discount rate of 13% and growth rate of 1%. However, risks such as platform limitations and competition from other bi

Bears say

Kodiak Sciences is a pre-commercial biotechnology company that is focused on developing transformative therapeutics for retinal diseases. However, the Negative Outlook stems from concerns about competition from other biotechnology companies that are also working on treatments for retinal diseases, as well as the potential for delays or setbacks in the approval process for Kodiak's investigational medicines. Additionally, the company's financials show a net loss for the quarter and a potential need for additional capital, which could lead to share dilution.

KOD has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 7 analysts, KOD has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.